Research

Battle of the Sexes: How Men and Women Respond Differently to Retatrutide

August 21, 20265 min read

The conversation around weight-loss medications is no longer just about if they work, but how they act differently from one body to the next. Retatrutide, Eli Lilly's highly anticipated experimental “triple-agonist” peptide, is making headlines for its ability to clear out liver fat and prompt average weight loss of up to 30%. ^{[1, 5]}

However, recent analysis of the clinical trial data reveals a compelling trend: men and women do not experience the exact same journey on retatrutide. While both sexes see unprecedented, boundary-breaking results, biological differences shape the percentage of weight lost, the types of side effects felt, and how fast the scale moves. ^{[1, 3]}

The Percentage Gap: Why Women Edge Ahead

When evaluating clinical data from retatrutide's testing phases, researchers noticed that women tend to lose a higher percentage of their starting body weight than men. On the maximum 12 mg weekly dose over 48 weeks, women averaged a 25.3% body-weight reduction, while men achieved a 22.8% reduction. ^{[1, 3, 5]}

This 2.5% gap might seem small, but it aligns perfectly with a broad 2025 systemic review and meta-analysis published in Journal of Diabetes Investigation. The study pooled data across multiple incretin therapies and proved that women consistently lose more relative weight than men—and interestingly, the more powerful the drug is, the wider the gender gap becomes. Because retatrutide is the strongest metabolic compound ever tested, this biological divide is more visible than ever before. ^{[2, 4]}

Table 1: Side-by-Side Response Metrics (12 mg Dose Profile)

Metric	Female Subgroup Response	Male Subgroup Response	The Biological “Why”
Relative Weight Loss	Higher (~25.3%)	Lower (~22.8%)	Women exhibit different central appetite brain circuitry and hormone sensitivity.
Absolute Pounds Lost	Lower	Higher	Men start at a significantly higher baseline body mass on average.
Nausea Rates	~31%	~24%	Smaller average frame sizes mean higher relative drug exposure per kilogram of mass.
Blood Sugar Control	Equal (1.6% drop)	Equal (1.6% drop)	Insulin stabilization and HbA1c reductions are non-gendered.

Muscle vs. Pounds: The Absolute Weight Paradox

While women win the “percentage of body weight” race, men typically lose more raw, absolute pounds. ^{[2, 4]}

Because men generally carry a higher baseline body mass and more skeletal muscle, their resting metabolic rate is significantly higher. When retatrutide's glucagon component kicks in—which intentionally speeds up metabolism and calorie expenditure—men often see the scale drop rapidly in the opening months of treatment. ^{[3, 5]}

Tracking Efficacy Curves Across 48 Weeks

Visualizing the timeline illustrates the subtle divergence between the sexes. Women drop steadily and consistently into deeper percentage territory, while men display an aggressive initial drop that settles into a slightly higher baseline plateau. ^{[1, 3]}

Retatrutide body weight loss trajectory over 48 weeks: female smooth trajectory to -25.3%, male sharp initial drop settling at -22.8% — Retatrutide body weight loss trajectory over 48 weeks (men vs. women), 12 mg dose profile.

Tolerability and Side Effects: Who Has It Harder?

Retatrutide is a heavy-duty metabolic tool, and its side effects follow the standard patterns of the GLP-1 drug class. However, the intensity of these symptoms is balanced differently between genders. ^{[1, 4]}

The Female Side Effect Profile: Women report slightly higher rates of GI distress, particularly nausea (31% vs 24% for men). Endocrinologists suggest this is due to pharmacokinetics—because women have lower average body weights, taking the standard 12 mg dose means they get a higher concentration of the medicine per pound of tissue than a larger male counterpart. ^{[1, 2]}

The Male Side Effect Profile: While men suffer less day-to-day nausea, they face higher risks associated with rapid muscle loss if they fail to eat enough protein while their appetite is suppressed. Men also must carefully track heart metrics, as retatrutide causes a temporary spike in resting heart rate via glucagon receptors. ^{[3, 5]}

Regardless of gender, the drug relies on the same progressive dose titration (starting at 2 mg and stepping up every 4 weeks) to allow the gut and brain time to naturally adapt. ^[5]

References

Ostrander, K. (2026). “Does Retatrutide Work Equally for Men and Women?” Health and Peptide Research, Red Fox Peptides.
Wang, Y., et al. (2025). “Sex Differences in the Efficacy of Glucagon‑Like Peptide‑1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.” Journal of Diabetes Investigation, Wiley Online Library.
Turner, R. (2026). “Retatrutide: Men vs Women, Who Really Loses More?” Metabolic Health Insights, Red Fox Peptides.
Buse, J. B., et al. (2025). “Sex differences in the weight response to GLP-1RA in people with type 2 diabetes.” ScienceDirect / Pharmacological Research, ScienceDirect.
Jastreboff, A. M., et al. (2023). “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicine, 389(6), 514-526.